Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Chi Lin

Showing results (161-170 of 231) with videos related to

Pageof 24
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 14, 2017
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, et al.
JTO Clinical and Research Reports|September 30, 2021
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in <i>EGFR</i> T790M-Positive NSCLCBin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2024
Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II studyJhe-Cyuan Guo, Ta-Chen Huang, Hung-Yang Kuo, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
British Journal of Cancer|March 21, 2026
Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinomaTa-Chen Huang, Jhe-Cyuan Guo, Chia-Chi Lin, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
JTO Clinical and Research Reports|September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase InhibitorsKeunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
BMC Cancer|March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerJanice M Mehnert, Andrea Varga, Marcia S Brose, et al.
Organic & Biomolecular Chemistry|June 6, 2018
Regioselective synthesis and biological evaluation of N-substituted 2-aminoquinazolin-4-onesZhen-Yuan Liao, Wen-Hsiung Yeh, Pen-Yuan Liao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 13, 2021
Thienoisoindigo (TII)-Based Quinoidal Small Molecules for High-Performance n-Type Organic Field Effect TransistorsArulmozhi Velusamy, Chih-Hsin Yu, Shakil N Afraj, et al.
Pageof 24

Showing results (161-170 of 231) with videos related to

Sort By:
Pageof 24
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 14, 2017
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, et al.
JTO Clinical and Research Reports|September 30, 2021
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in <i>EGFR</i> T790M-Positive NSCLCBin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2024
Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II studyJhe-Cyuan Guo, Ta-Chen Huang, Hung-Yang Kuo, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
British Journal of Cancer|March 21, 2026
Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinomaTa-Chen Huang, Jhe-Cyuan Guo, Chia-Chi Lin, et al.
Cancer Science|November 29, 2019
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohortsYung-Jue Bang, Wu-Chou Su, Martin Schuler, et al.
JTO Clinical and Research Reports|September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase InhibitorsKeunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
BMC Cancer|March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerJanice M Mehnert, Andrea Varga, Marcia S Brose, et al.
Organic & Biomolecular Chemistry|June 6, 2018
Regioselective synthesis and biological evaluation of N-substituted 2-aminoquinazolin-4-onesZhen-Yuan Liao, Wen-Hsiung Yeh, Pen-Yuan Liao, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 13, 2021
Thienoisoindigo (TII)-Based Quinoidal Small Molecules for High-Performance n-Type Organic Field Effect TransistorsArulmozhi Velusamy, Chih-Hsin Yu, Shakil N Afraj, et al.
Pageof 24